文献速递肺栓塞与肺血管病

遗传性与散发性肺静脉闭塞病的临床表型与结局:一项基于人群的研究

Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.
PubMed 文献 · Lancet Respir Med · 2017-01-11

该研究基于法国肺动脉高压网络登记数据,纳入94例确诊或高度疑似PVOD/PCH患者,其中29%携带双等位EIF2AK4突变。靶向药物应答率极低(仅4%达到满意临床应答),无事件生存率两组无显著差异。

要点

  • 双等位EIF2AK4突变携带者诊断年龄显著年轻于非携带者。
  • PVOD/PCH患者对肺动脉高压靶向药物满意应答率仅4%。
  • 携带者与非携带者无事件生存率无显著差异,肺移植应作为 eligible 患者的考虑选项。

核心结论

  • 双等位EIF2AK4突变所致遗传性PVOD/PCH诊断年龄更轻,但疾病严重程度与未携带者相似。
  • PVOD/PCH对肺动脉高压靶向治疗应答罕见,肺移植应作为符合条件的患者的考虑选项。

研究设计与样本

  • 基于法国肺动脉高压网络登记数据的基于人群研究,纳入2003年1月1日至2016年6月1日期间确诊或高度疑似PVOD/PCH且DNA可供突变筛查的患者。
  • 共纳入94例散发性或遗传性PVOD/PCH患者,排除其他肺动脉高压危险因素(如慢性呼吸系统疾病)。
  • 对EIF2AK4基因编码序列及内含子交界区进行测序,比较突变携带者与非携带者的临床特征和结局。

主要发现

  • 94例患者中27例(29%)携带双等位EIF2AK4突变。
  • 诊断时携带者与非携带者均表现为相似严重程度的毛细血管前性肺动脉高压和功能损害。
  • 携带者中22例(81%)、非携带者中63例(94%)接受肺动脉高压靶向药物治疗;药物诱导性肺水肿在携带者中5例(23%)、非携带者中13例(21%)。

关键数值与推荐

  • 肺移植后1年、2年、5年估计生存率分别为84%、81%、73%。

临床怎么用

  • 对年轻PVOD/PCH患者应行EIF2AK4基因检测以明确遗传性病因。
  • 肺动脉高压靶向药物在PVOD/PCH中应答率极低,需密切监测药物诱导性肺水肿。
  • 符合条件的PVOD/PCH患者应尽早评估肺移植。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bi-allelic mutations of the EIF2AK4 gene cause heritable pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis (PVOD/PCH). We aimed to assess the effect of EIF2AK4 mutations on the clinical phenotypes and outcomes of PVOD/PCH. METHODS: We did a population-based study using clinical, functional, and haemodynamic data from the registry of the French Pulmonary Hypertension Network. We reviewed the clinical data and outcomes from all patients referred to the French Referral Centre (Pulmonary Department, Hospital Kremlin-Bicêtre, University Paris-Sud) with either confirmed or highly probable PVOD/PCH with DNA available for mutation screening (excluding patients with other risk factors of pulmonary hypertension, such as chronic respiratory diseases). We sequenced the coding sequence and intronic junctions of the EIF2AK4 gene, and compared clinical characteristics and outcomes between EIF2AK4 mutation carriers and non-carriers. Medical therapies approved for pulmonary arterial hypertension (prostacyclin derivatives, endothelin receptor antagonists and phosphodiesterase type-5 inhibitors) were given to patients according to the clinical judgment and discretion of treating physicians. The primary outcome was the event-free survival (death or transplantation). Secondary outcomes included response to therapies for pulmonary arterial hypertension and survival after lung transplantation. A satisfactory clinical response to specific therapy for pulmonary arterial hypertension was defined by achieving New York Heart Association functional class I or II, a 6-min walk distance of more than 440 m, and a cardiac index greater than 2·5 L/min per m2 at the first reassessment after initiation of specific therapy for pulmonary arterial hypertension. FINDINGS: We obtained data from Jan 1, 2003, to June 1, 2016, and identified 94 patients with sporadic or heritable PVOD/PCH (confirmed or highly probable). 27 (29%) of these patients had bi-allelic EIF2AK4 mutations. PVOD/PCH due to EIF2AK4 mutations occurred from birth to age 50 years, and these patients were younger at presentation than non-carriers (median 26·0 years [range 0-50.3] vs 60·0 years [6·7-81·4] years; p<0·0001). At diagnosis, both mutations carriers and non-carriers had similarly severe precapillary pulmonary hypertension and functional impairment. 22 (81%) of mutations carriers and 63 (94%) of non-carriers received therapy approved for pulmonary arterial hypertension. Drug-induced pulmonary oedema occurred in five (23%) of treated EIF2AK4 mutations carriers and 13 (21%) of treated non-carriers. Follow-up assessment after initiation of treatment showed that only three (4%) patients with PVOD/PCH reached the predefined criteria for satisfactory clinical response. The probabilities of event-free survival (death or transplantation) at 1 and 3 years were 63% and 32% in EIF2AK4 mutations carriers, and 75% and 34% in non-carriers. No significant differences occurred in event-free survival between the 2 groups (p=0·38). Among the 33 patients who had lung transplantation, estimated post-transplantation survival rates at 1, 2, and 5 years were 84%, 81%, and 73%, respectively. INTERPRETATION: Heritable PVOD/PCH due to bi-allelic EIF2AK4 mutations is characterised by a younger age at diagnosis but these patients display similar disease severity compared with mutation non-carriers. Response to therapy approved for pulmonary arterial hypertension in PVOD/PCH is rare. PVOD/PCH is a devastating condition and lung transplantation should be considered for eligible patients. FUNDING: None.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Montani D, Girerd B, Jaïs X, et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med. 2017. PMID: 28087362. doi:10.1016/S2213-2600(16)30438-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。